CK-666和CK-869差异性抑制Arp2/3的异构复合物
LuYan Cao1, Shaina Huang2, Angika Basant2
1The Francis Crick Institute, London, UK. luyan.cao@crick.ac.uk.
EMBO reports
|July 15, 2024
概括
Arp2/3复合体抑制剂CK-666和CK-869对哺乳动物异构复合体具有差异性活性. 它们在抑制actin核和分支的有效性取决于特定的亚单元组成,影响细胞功能,如迁移.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- Arp2/3复合体对于行为核和细胞过程至关重要.
- CK-666和CK-869是用于Arp2/3复合函数的常见化学探针.
- 由于基因重复,哺乳动物Arp2/3复合体存在多个异构复合体.
研究的目的:
- 调查CK-666和CK-869对不同Arp2/3异构复合物的差异性活性.
- 为了确定异构复合物组成如何影响抑制剂在actin核和分支中的有效性.
- 澄清异构体异质性对解释实验结果的影响.
主要方法:
- 使用了具有定义子单元组成的重组Arp2/3复合体.
- 评估了CK-666和CK-869对线性活性丝的形成和分支的活性.
- 检查了骨髓衍生的巨细胞中对细胞形成和细胞迁移的抑制作用.
主要成果:
- 无论是CK-666还是CK-869,都在不同的ArpC1异构复合体中抑制线性活性蛋白的形成.
- 动氨酸分支抑制是依赖于异构复合物的:这两种药物都抑制了ArpC1A复合物,但只有CK-869抑制了ArpC1B复合物.
- CK-869,但不是CK-666,损害了巨细胞的吞和迁移,与低ArpC1A表达相关.
结论:
- CK-666和CK-869的疗效受到Arp2/3异构复合物组成的显著影响.
- 与CK-666.6相比,CK-869对ArpC1和Arp3异构复合体具有更广泛的抑制活性.
- 这些发现需要在解释使用这些抑制剂的研究时仔细考虑Arp2/3异构复合体表达.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
550
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
550


